Quality Assurance and Safety of Herbal Dietary Supplements

10.1021/cen-v082n016.p045

Lee F SC, Am Chem Soc Monograph

2003, FDA Proposal for Dietary Supplements Current. Good Manufacturing Practices (CGMPs)

2003, Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants

Hu S L, 1997, A study of Chinese genuine herbs

Chan S S, 2007, J Food Drug Anal, 15, 365

10.1080/10590500701569414

Liu Y, 2007, Guangpuxue Yu Guangpu Fenxi, 27, 1093

Chen J, 2007, Food Drug Anal, 15, 347

10.1016/j.jep.2006.12.018

10.1055/s-2005-916199

10.1248/cpb.55.140

Wu J, 2004, J AOAC Int, 87, 1260, 10.1093/jaoac/87.5.1260

10.1002/ptr.1694

Hao L L, 2005, Zhongguo Zhong Yao Za Zhi, 30, 405

10.1300/J157v06n02_01

Lai L, 2006, Executive Yuan, 24, 228

Lai L, 2006, Executive Yuan, 24, 242

Lai L, 2006, Executive Yuan, 24, 257

Lai L, 2006, Executive Yuan, 24, 265

Wong T C, 2007, J Food Drug Anal, 15, 472

Mustafa O, 2007, J Food Drug Anal, 15, 55

FDA. 2005. Warning on Imported Ginseng.FDA Consumer, 39(2)

10.1007/BF00902296

10.1001/jama.285.21.2705

2001, Dietary Supplements: Aristolochic Acid

10.1056/NEJM200310163491619

10.1007/s00216-007-1310-3

10.1080/15563650600671712

Yang H Y, 2006, J Nephrol, 19, 111

2002, IARC monographs on the evaluation of carcinogenic risks of chemical to humans

10.1056/NEJM200006083422301

Vanherweghem J L, 1995, Nephrol Dial Transplant, 10, 270

10.1007/BF00295084

10.1007/BF01973700

10.1093/carcin/22.1.133

10.1016/0165-7992(82)90031-8

10.1016/j.fct.2004.07.016

10.1007/BF00333900

10.1007/BF00293699

10.1016/S0140-6736(01)06576-X

10.1016/0041-0101(87)90155-3

10.1016/0140-6736(93)92984-2

10.1038/ki.1994.220

Depierreux M, 1994, Am J Kidney Dis, 24, 172, 10.1016/S0272-6386(12)80178-8

10.1089/acm.1998.4.1-9

10.1016/S0140-6736(94)90964-4

10.1093/ndt/18.2.426

10.1093/ndt/17.3.524

Schmeiser H H, 1996, Cancer Res, 56, 2025

10.1053/j.ajkd.2003.11.024

10.1002/ijc.20316

10.1093/mutage/gei007

Cosyns J P, 2001, Kidney Int, 59, 2164, 10.1046/j.1523-1755.2001.00731.x

Gold L, 1997, Handbook of carcinogenic potency and genotoxicity databases

10.1016/j.toxlet.2006.04.008

10.1186/1471-2105-7-S2-S20

Chen T, 2007, J Food Drug Anal, 15, 387

10.1056/NEJM200006083422309

10.1001/jama.285.21.2705

2008, Report on Carcinogens Background Document for Aristolochic Acid

1976, IARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals to Man—Some Naturally Occurring Substance, 10, 265

Mattocks A R, 1986, Chemistry and toxicology of pyrrolizidine alkaloids

10.1081/DMR-120028426

10.1016/S0378-4274(03)00240-6

Molyneux J O, 1990, Vet Hum Toxicol, 32, 94

10.1002/jps.2600830511

Prakash A S, 1999, Mutat Res, 443, 53, 10.1016/S1383-5742(99)00010-1

Chou M W, 2006, Toxicol Ind Health, 22, 321, 10.1177/0748233706071765

1989, Pyrrolizidine Alkaloids Health and Safety Guide. Health and Safety Criteria Guide 26

10.1021/tx000150n

10.1021/tx030018y

10.1016/S0304-3835(03)00045-4

10.1021/tx025605i

National Toxicology Program (NTP). 2008. Report on Carcinogens.Federal Register, 73(84)

Fu P P, 2007, J Food Drug Anal, 15, 400

Roeder E, 2000, Pharmazie, 55, 711

McLean E K, 1970, Pharmacol Rev, 22, 429

Lin G, 2000, Drug Metab Dispos, 28, 1475

Fu P P, 2002, J Food Drug Analy, 10, 198

10.1002/rcm.3398

10.1177/0748233708093727

10.1016/j.canlet.2004.11.039

10.1021/tx030030q

10.1016/j.canlet.2005.01.023

10.1016/j.toxlet.2008.02.008

Mossoba M M, 1994, J AOAC Int, 77, 1167, 10.1093/jaoac/77.5.1167

Snider S, 1991, FDA Consumer, 25, 30

10.1021/ed064p1027

D'Arcy P F, 1991, Adverse Drug React Toxicol Rev, 10, 189

10.1007/s11606-005-0114-4

Rowin J, 1996, Neurology, 46, 1775, 10.1212/WNL.46.6.1775

10.1016/j.jep.2006.03.014

10.1080/10715760000301141

10.1016/j.bbrc.2005.10.031

10.1021/tx990161k

10.1016/j.fct.2004.12.012

10.1016/S0006-2952(03)00151-5

10.1021/tx050201m

10.1016/0278-6915(87)90301-2

1992, Toxicology and Carcinogenesis Studies of Quercetin

10.1016/j.toxlet.2003.07.005

10.1016/j.jep.2005.05.014

10.1080/10590500801907407

10.1081/CLT-120019123

10.1016/S0168-8278(03)00175-2

2002, U.S. Food and Drug Administration. A Consumer Advisory. Kava-containing dietary supplements may be associated with severe liver injury

10.1016/S0031-9422(03)00381-9

10.1016/S0169-409X(97)00042-2

Mathews J D, 1988, Med J Aust, 148, 548, 10.5694/j.1326-5377.1988.tb93809.x

10.1016/S0024-3205(02)01913-6

10.1124/dmd.30.11.1153

10.1124/dmd.105.004317

Bressler R, 2005, Geriatrics, 60, 24

10.2165/00003495-200565090-00005

10.1016/j.etp.2006.08.002

10.1053/jhep.2001.21083

10.1021/tx020113r

Available at:http://www.cfsan.fda.gov/~dms/dscgmps7.htmlFederal Register. Final Rule and Interim final rule. June 25, 2007